Aurobindo Pharma & promoters fined Rs22.7cr by Sebi on violation of norms - Highlight Investment Research

Breaking

We are Best advisory company and SEBI Registered Investment Adviser in India, We Provide sure shot call and 100% Research Based Calls to our clients.

Tuesday, 24 September 2019

Aurobindo Pharma & promoters fined Rs22.7cr by Sebi on violation of norms


Aurobindo Pharma
AurobindoPharmaceuticals Ltd. was fined Rs22.7cr by Sebi on Monday, according to media reports.

The pharma company and its promoters were penalized for violation of provisions of insider trading in relation to a licensing deal it had entered with Pfizer in 2009, reports said.


Sebi imposed Rs5cr penalty on PV Ramaprasad Reddy, Rs2cr on his wife P Suneela Rani, Rs10 lakh on Kambam P Reddy, Rs6cr on Trident Chemphar, Rs10 lakh on Veritaz Health Care, Rs7.5cr on Top Class Capital Markets under Section 15G of SEBI Act, and Rs2cr on Aurobindo Pharma under Section 23E of Securities Contracts (Regulation) Act and Section 15HB of SEBI Act, according to SEBI’s adjudicating order.

Aurobindo Pharma Ltd is currently trading at Rs608.85 down by Rs4.95 or 0.81% from its previous closing of Rs613.80 on the BSE.

No comments:

Post a Comment